Hikma Pharmaceuticals PLC (HIK)

2,026.00
+26.00(+1.30%)
  • Volume:
    720,536
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    2,002.00 - 2,046.00

HIK Overview

Prev. Close
2,000
Day's Range
2,002-2,046
Revenue
1.79B
Open
2,015
52 wk Range
1,976-2,703
EPS
1.49
Volume
720,536
Market Cap
4.69B
Dividend (Yield)
0.38
(1.89%)
Average Volume (3m)
343,774
P/E Ratio
13.42
Beta
0.19
1-Year Change
-19.81%
Shares Outstanding
231,457,224
Next Earnings Date
24 Feb 2022
What is your sentiment on Hikma Pharmaceuticals PLC?
or
Market is currently closed. Voting is open during market hours.

Hikma Pharmaceuticals PLC Company Profile

Employees
8600

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The Company's segments include Branded, Injectables, Generics and Others. The Company provides non-injectable and injectable generic medicines in the United States. It provides branded generic medicines and generic injectable products across the Middle East and North Africa (MENA). It also provides generic injectable medicines in Europe and other markets around the world. The Company's other businesses comprise Arab Medical Containers (AMC), a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellSell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
  • Touch 27 today
    0
    • Next results will be super. Wait for it to hit £32 before end of this year
      0
      • Aim listed Dark Matter Ltd, has more potential
        1
        • This will go up & up
          1
          • Not as stated here (March 11)
            1
            • Hikma will announce their results for the year ended 31 December 2019 on 27 February 2020
              0
              • Any hint of progress on Advair will send this stock much higher still !
                0
                • Underpriced without the Advair approvals ' unfortunate about the 2019 target for Advair !!!
                  0
                  • Almost got me money back !!!
                    0
                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.